title: [Platelet aggregation during the recombinant human erythropoietin (rHuEPO) treatment of patients with uremia].
abstract: Patients with uraemia have a defect haemostasis caused by severe anaemia and disturbances of platelet/vessel wall interactions. Recombinant human erythropoietin (rHuEPO) treatment not only corrects anaemia, but also shortens the bleeding time. There are few reports dealing with changes of haemostasis during the first month of rHuEPO treatment. We studied platelet function after 1, 2, 4, 8, and 12 weeks of rHuEPO treatment. Erythropoietin was given to 19 dialysed patients with chronic uraemia in a dose of 2000 u subcutaneously 3 times a week. Bleeding time showed a significant fall as early as after the first week of rHuEPO treatment (p < 0.05). After the first month the bleeding time became normal in most of the patients. A significant rise in ristocetin-induced platelet aggregation was observed from the first week of therapy. It showed a strong correlation with the shortening of the bleeding time. Collagen-induced aggregation followed the same pattern but the changes were not striking. There was not significant difference in platelet adhesion, platelet aggregation in the whole blood and those induced by ADP and arachidonic acid. Platelet serotonin concentration was also showed to increase during rHuEPO therapy. We conclude that rHuEPO improves haemostasis by influencing platelet aggregation possibly involving a serotoninergic mechanism but on the other hand may increase a tendency to thrombosis.
authors: Klinika Nefrologii Akademii Medycznej, Białymstoku.
authors: M
authors: M
authors: Mazerska
authors: K
authors: K
authors: Pawlak
authors: A
authors: A
authors: Azzadin
authors: J
authors: J
authors: Małyszko
authors: J
authors: J
authors: Małyszko
authors: M
authors: M
authors: Myśliwiec
authors: W
authors: W
authors: Buczko
mesh_terms: D000328:Adult; D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D001760:Bleeding Time; D002908:Chronic Disease; D004921:Erythropoietin / Q000235:genetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects / Q000502:physiology*; D011995:Recombination, Genetic; D006435:Renal Dialysis; D014511:Uremia / Q000097:blood* / Q000150:complications / Q000628:therapy
chemical_list: D004921:Erythropoietin
vernacular_title: Agregacja płytek krwi podczas leczenia erytropoetyna (rHuEPO) pacjentów z mocznica.